content top

Combination Therapy of Photodynamic Therapy with Verteporfin and Intravitreal Pegaptanib in the Management of Exudative ARMD

Posted by and on Oct 1, 2006 in ARMD, Choroidal new vessels, Pegaptanib Macugen, Photodynamic therapy PDT

Asheesh Tewari, MD (St. Louis, MO), Rajendra S. Apte, MD, PhD (St. Louis, MO)* PURPOSE: To examine outcomes of a group of previously treatment naïve patients treated with combined photodynamic therapy with verteporfin and intravitreal pegaptanib for choroidal neovascularization secondary to ARMD. METHODS: Retrospective review of ten eyes of ten consecutive patients with CNV secondary to ARMD. These patients had  not received  any prior...

Read More

Retrospective Analysis of All Cases of Endophthalmitis at a Tertiary Referral Center

Posted by and on Oct 1, 2006 in Etiology - Epidemiology, Postoperative (endophthalmitis)

Rajendra S. Apte, MD, PhD (St. Louis, MO), Humeyra Karacal, MD (St. Louis, MO) PURPOSE: To determine the incidence, etiology and visual outcomes of endophthalmitis in a large Universitybased retina practice. METHODS: 40,371 patients were seen at Barnes Retina Institute between 2000 and 2005, and 1,872 patients had intravitreal injections during same time period. 68 cases of endophthalmitis were identified and reviewed retrospectively for...

Read More

Macrophages Inhibit Neovascularization in a Murine Model of Agerelated Macular Degeneration (AMD)

Posted by , , and on Oct 1, 2006 in ARMD, Choroidal new vessels, Experimental Study, Neovascularization / angiogenesis

Rajendra S. Apte, MD, PhD (St. Louis, MO), Thomas A. Ferguson, PhD (St. Louis, MO), Jennifer Richter, BS (St. Louis, MO), John Herndon, BS (St. Louis, MO) PURPOSE: CNV is the process by which abnormal blood vessels develop underneath the retina and lead to blindness in over 90% of patients with AMD. Although the precise etiology of CNV in AMD remains unknown, the macrophage component of the inflammatory response has been thought to be...

Read More
content top